Últimas noticias sobre MeiraGTx Hldgs (NASDAQ:MGTX) Bolsa

MeiraGTx Hldgs

MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.

MeiraGTx Holdings PLC

B of A Securities analyst Craig Siegenthaler upgrades Brookfield Asset Mgmt (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAM#NYSE">BAM</a>) from Neutral to Buy and maintains the price target from $65 to $65.

News

Upgrades

Price Target

Analyst Ratings

B of A Securities Upgrades Brookfield Asset Mgmt to Buy, Maintains Price Target to $65

<ul>
<li>Combined business to be renamed Elevra Lithium upon merger completion</li>
<li>Elevra Lithium Board of Directors Nominees named with four members from each standalone business select</li>
</ul>

Piedmont Lithium And Sayona Mining To Merge As Elevra Lithium; Board Nominees Announced

B of A Securities analyst Joshua Dennerlein initiates coverage on MSCI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSCI#NYSE">MSCI</a>) with a Neutral rating and announces Price Target of $585.

Initiation

MSCI

B of A Securities Initiates Coverage On MSCI with Neutral Rating, Announces Price Target of $585

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the<a href="https://www.benzinga.com/topic/rsi"> RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Edgewise Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWTX#NASDAQ">EWTX</a>)</h3>
<ul>
<li>On April 2, Edgewise Therapeutics priced an underwritten public offering of 9.94 million shares at $20.13 per share, expecting to raise approximately $200 million. The offering is set to close on April 3, pending customary conditions. The company's stock fell around 55% over the past month and has a 52-week low of $10.60.</li>
<li>RSI Value: 27.5</li>
<li>EWTX Price Action: Shares of Edgewise Therapeutics gained 8.8% to close at $12.50 on Wednesday.</li>
<li>Edge Stock Ratings: 15.43 Momentum score. </li>
</ul>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/quote/ewtx"><img loading="lazy" decoding="async" width="493" height="173" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10043318/image-59.png" alt="" class="wp-image-865422" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10043318/image-59.png 493w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10043318/image-59-300x105.png 300w" sizes="(max-width: 493px) 100vw, 493px" /></a></figure>
<h3 class="wp-block-heading">Genfit SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNFT#NASDAQ">GNFT</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On Feb. 7, HC Wainwright &amp; Co. analyst Ed Arce reiterated Genfit with a Buy rating and maintained a $13 price target. The company's stock fell around 27% over the past five days and <a href="https://www.benzinga.com/quote/GNFT">has a 52-week low</a> of $2.55.</li>
<li>RSI Value: 29.3</li>
<li>GNFT Price Action: Shares of Genfit dipped 21.4% to close at $2.64 on Wednesday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0410">GNFT stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0410"><img loading="lazy" decoding="async" width="921" height="832" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10043427/image-60.png" alt="" class="wp-image-865424" style="width:597px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10043427/image-60.png 921w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10043427/image-60-300x271.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10043427/image-60-768x694.png 768w" sizes="(max-width: 921px) 100vw, 921px" /></a></figure>
<h3 class="wp-block-heading">CAMP4 Therapeutics Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMP#NASDAQ">CAMP</a>)</h3>
<ul>
<li>On March 27, CalAmp reported a quarterly loss of $11.04 per share which met the analyst consensus estimate. &#8220;We are off to a strong start in 2025, building on the momentum of a successful 2024, which included advancing our Phase 1 clinical program in UCDs, establishing key research collaborations, securing important regulatory designations, and completing our initial public offering,&#8221; said Josh Mandel-Brehm, Chief Executive Officer of CAMP4. The company's stock fell around 49% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/CAMP">low of $0.39.</a></li>
<li>RSI Value: 23.1</li>
<li>CAMP Price Action: Shares of CAMP4 Therapeutics dipped 7.4% to close at $2.14 on Wednesday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0410">CAMP shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0410"><img loading="lazy" decoding="async" width="886" height="826" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10043516/image-61.png" alt="" class="wp-image-865425" style="width:416px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10043516/image-61.png 886w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10043516/image-61-300x280.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10043516/image-61-768x716.png 768w" sizes="(max-width: 886px) 100vw, 886px" /></a></figure>
Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and s<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">ee how they compare.</a> 
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44710375/top-2-materials-stocks-that-may-fall-off-a-cliff-this-quarter">Top 2 Materials Stocks That May Fall Off A Cliff This Quarter</a> </li>
</ul>
Photo via Shutterstock

Long Ideas

Pre-Market Outlook

Markets

Trading Ideas

CAMP

EWTX

GNFT

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q2

The Buckle, &nbsp;comparable store net sales, for stores open at least one year, for the 5-week period ended April 5, 2025 increased 3.7 percent from comparable store net sales for the 5-week period ended April 6, 2024. Net sales for the 5-week fiscal month ended April 5, 2025 increased 4.5 percent to $109.1 million from net sales of $104.3 million for the prior year 5-week fiscal month ended April 6, 2024.

Buckle Reports 4.5% YoY Increase In March Net Sales To $109.1M; Comparable Store Sales Rise 3.7%

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Microbot Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBOT#NASDAQ">MBOT</a>) with a Buy and maintains $9 price target.

Reiteration

MBOT

HC Wainwright & Co. Reiterates Buy on Microbot Medical, Maintains $9 Price Target

B of A Securities analyst Craig Siegenthaler downgrades Cboe Global Markets (BATS:<a class="ticker" href="https://www.benzinga.com/stock/CBOE#BATS">CBOE</a>) from Buy to Neutral and lowers the price target from $260 to $227.

Downgrades

CBOE

B of A Securities Downgrades Cboe Global Markets to Neutral, Lowers Price Target to $227

B of A Securities analyst Federico Merendi initiates coverage on Phinia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHIN#NYSE">PHIN</a>) with a Buy rating and announces Price Target of $53.

PHIN

B of A Securities Initiates Coverage On Phinia with Buy Rating, Announces Price Target of $53

Needham analyst Ryan MacDonald reiterates Docebo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCBO#NASDAQ">DCBO</a>) with a Buy and maintains $42 price target.

DCBO

Needham Reiterates Buy on Docebo, Maintains $42 Price Target

CarMax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMX#NYSE">KMX</a>) reported quarterly earnings of $0.58 per share which missed the analyst consensus estimate of $0.68 by 14.71 percent. This is a 81.25 percent increase over earnings of $0.32 per share from the same period last year. The company reported quarterly sales of $6.00 billion which beat the analyst consensus estimate of $5.96 billion by 0.67 percent. This is a 6.68 percent increase over sales of $5.63 billion the same period last year.

Earnings

Earnings Beats

Earnings Misses

CarMax Q4 2025 GAAP EPS $0.58 Misses $0.68 Estimate, Sales $6.00B Beat $5.96B Estimate

B of A Securities analyst Caio Ribeiro upgrades Vale (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VALE#NYSE">VALE</a>) from Neutral to Buy and raises the price target from $11 to $11.5.

VALE

B of A Securities Upgrades Vale to Buy, Raises Price Target to $11.5

B of A Securities analyst Christopher Nardone upgrades Levi Strauss (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>) from Neutral to Buy and raises the price target from $17 to $20.

LEVI

B of A Securities Upgrades Levi Strauss to Buy, Raises Price Target to $20

HC Wainwright &amp; Co. analyst Joseph Pantginis downgrades Tempest Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPST#NASDAQ">TPST</a>) from Buy to Neutral and maintains the price target from $16 to $16.

Tempest Therapeutics, Inc. - Common Stock

TPST

HC Wainwright & Co. Downgrades Tempest Therapeutics to Neutral, Maintains Price Target to $16

Needham analyst Scott Berg reiterates Thryv Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRY#NASDAQ">THRY</a>) with a Buy and maintains $28 price target.

THRY

Needham Reiterates Buy on Thryv Holdings, Maintains $28 Price Target

<a href="https://x.com/vonderleyen/status/1910278392349327628" title="https://x.com/vonderleyen/status/1910278392349327628">https://x.com/vonderleyen/status/1910278392349327628</a>

Macro Economic Events

Economics

EU's Ursula von der Leyen on X Said "We took note of the announcement by President Trump. We want to give negotiations a chance. While finalising the adoption of the EU countermeasures that saw strong support from our Member States, we will put them on hold for 90 days."

Former President Donald Trump recently issued an executive order to revise the federal definition of a &#8220;shower head.&#8221; The decision is framed as an effort to counter what he called the &#8220;Obama-Biden war on water pressure.&#8221;
What Happened: The White House announced that the order is designed to &#8220;make America&#8217;s showers great again.&#8221; The order will impact various&nbsp;household appliances, including toilets and&nbsp;sinks. Trump has frequently voiced his dissatisfaction with the&nbsp;water pressure in American showers,&nbsp;sinks, and toilets, blaming&nbsp;federal water-conservation standards for the&nbsp;issue.
During the signing of the <a href="https://www.whitehouse.gov/fact-sheets/2025/04/fact-sheet-president-donald-j-trump-makes-americas-showers-great-again/">executive order</a>, Trump stated, &#8220;In&nbsp;my case, I like to&nbsp;take a nice shower to&nbsp;take care of my beautiful&nbsp;hair. I&nbsp;have to stand under the&nbsp;shower for 15 minutes until&nbsp;it gets wet. It comes&nbsp;out drip, drip, drip. It&#8217;s ridiculous.&#8221;
See Also:&nbsp;<a href="https://benzinga.com/25/04/44708103/why-investors-should-watch-chinas-service-trade-amid-us-tariff-escalation-disney-and-imax-most-impacted" target="_blank" rel="noreferrer noopener">China May Hit US Where It Hurts Amid Trump&#8217;s Tariff War — Services Trade In Crosshairs, With Walt Disney, IMAX And Warner Bros. Discovery In Focus</a>
The White House added, &#8220;By&nbsp;restoring shower freedom, President Trump&nbsp;is following through on his&nbsp;commitment to dismantle unnecessary regulations&nbsp;and put Americans first.&#8221;
Why It Matters: Trump&#8217;s emphasis on American water pressure has caught the attention of appliance experts.&nbsp;Andrew deLaski, executive director at&nbsp;the Appliance Standards Awareness Project,&nbsp;found it &#8220;very striking&#8221;&nbsp;that the White House memo&nbsp;included toilets and shower heads&nbsp;as a presidential priority, <a href="https://www.theguardian.com/us-news/2025/apr/09/trump-water-pressure-executive-order">reported</a> The Guardian.
While the impact of this executive order on the appliance industry and water conservation efforts is yet to be seen, it certainly marks a shift in the administration&#8217;s focus towards domestic issues. The order could potentially lead to changes in manufacturing standards and practices, impacting both consumers and manufacturers.
As he has done since the beginning of his second term, President Trump signed a series of executive orders this week, including ones aimed at <a href="https://www.benzinga.com/25/04/44704472/coal-stocks-rally-as-trump-signs-executive-order-to-revive-industry">boosting the coal industry</a>, <a href="https://in.benzinga.com/markets/25/03/44550693/trump-signs-executive-order-to-combat-crime-and-toughen-immigration-enforcement-in-washington-d-c">improving public safety in D.C</a>., and investigating former officials like Christopher Krebs and Miles Taylor. He also sanctioned the law firm Susman Godfrey over its involvement in Dominion Voting Systems&#8217; defamation suit against Fox News. Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next:&nbsp;<a href="https://benzinga.com/general/education/25/04/44705581/nvidia-supplier-asmls-ceo-wants-young-leaders-to-stop-asking-him-this-absurd-but-common-question-and-do-this-instead" target="_blank" rel="noreferrer noopener">Nvidia-Supplier ASML&#8217;s CEO Wants Young Leaders To Stop Asking Him This &#8216;Absurd&#8217; But Common Question And Do This Instead &#8211; Benzinga</a>

Government

Politics

General

Trump Declares War On Weak Showers With New Executive Order On Water Pressure: 'I Like To Take A Nice Shower To Take Care Of My Beautiful Hair'

Hedge fund titan Bill Ackman&#8217;s Pershing Square Holdings, a closed-end fund listed on the London Stock Exchange, is down 14% year-to-date, owing to tariff-related market volatility.
The losses, however, have only been calculated through April 8th, and don&#8217;t include the massive rally on Wednesday.
What Happened: Ackman&#8217;s fund allocates capital across 8 to 12 stocks, which are usually large-cap, liquid, and North American-based. 
The fund&#8217;s holdings during the past couple of months, comprising Nike Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>), Chipotle Mexican Grill Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>), and Hilton Hotels Corp. (NYSE:&nbsp;HLT), among others, none of which have performed well over the past few months, posting year-to-date declines of 19.48%, 14.96%, and 10.80%, respectively.
See More: <a href="https://www.benzinga.com/25/04/44730103/us-bike-prices-set-to-soar-amid-escalating-china-trade-war">Americans Could Pay 50% More For Bicycles As Trump&#8217;s Tariffs Hit China-Dependent Industry: Report</a>
Even its relatively well-insulated holdings, such as Google-parent Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) and Howard Hughes Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HHH#NYSE">HHH</a>), haven&#8217;t performed too well, declining 15.51% and 11% year-to-date, respectively.
Holdings gained during this period include Uber Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>), Federal National Mortgage Association (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FNMA#OTC">FNMA</a>), and the Federal Home Loan Mortgage Corp. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FMCC#OTC">FMCC</a>), gaining 15.05%, 75%, and 49.85%, respectively.
Why It Matters: Bill Ackman&#8217;s Pershing Square Holdings has generated a <a href="https://pershingsquareholdings.com/performance/net-asset-value-and-returns/">compounded annual NAV</a> return of 22.2% over the past five years. Ackman is also known for generating one of the industry&#8217;s highest returns of 70.2% in 2020, betting that the market would crash during the COVID-19 pandemic, making $2.2 billion for his investors.
This has positioned him as a trendsetter in the industry, whose portfolio is regularly watched to understand where the market is headed. He is also one of the most outspoken individuals on Wall Street, having made the news several times over the past few days alone.
On Wednesday, Bill Ackman praised Trump for <a href="https://www.benzinga.com/news/global/25/04/44723751/billionaire-investor-bill-ackman-praises-trumps-tariff-pause-thank-you-on-behalf-of-all-americans">pausing the tariffs</a>, before that he <a href="https://benzinga.com/markets/equities/25/04/44661978/bill-ackman-blames-market-collapse-on-tariff-timing-says-trump-advisor-should-be-fired-now-predicts-a-lot-more-than-5-dip">criticized the timing</a> of the tariffs, <a href="https://benzinga.com/government/regulations/25/04/44662730/bill-ackman-slams-commerce-secretary-lutnick-for-ignoring-stock-market-crash-he-and-cantor-are-long-bonds">slammed Commerce Secretary</a> Howard Lutnick, and more, all over the past week. 
Price Action: Pershing Square Holdings stock was up 8.14% on Wednesday, closing at 3,508 GBX, and is down 12.08% year-to-date.
Read More:
<ul>
<li><a href="https://www.benzinga.com/25/04/44730016/bitcoin-will-decouple-with-stocks-in-case-of-a-tariff-fueled-recession-says-analyst-lower-interest-rates-and-massive-money-printing">Bitcoin Could Break Free From Stocks In Case Of A Tariff-Fueled Recession, Says Analyst: &#8216;Lower Interest Rates And Massive Money Printing&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

Equities

FMCC

FNMA

GOOG

GOOGL

UBER

Bill Ackman Feels The Sting: Pershing Square Portfolio Down 14% Year-To-Date Amid Tariff Volatility

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Evolus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOLS#NASDAQ">EOLS</a>) with a Buy and maintains $27 price target.

EOLS

HC Wainwright & Co. Reiterates Buy on Evolus, Maintains $27 Price Target

After President Donald Trump announced a 90-day pause on most tariffs, U.S. <a href="https://www.benzinga.com/markets/equities/25/04/44726524/us-futures-edge-higher-nikkei-surges-8-as-trumps-90-day-tariff-pause-triggers-historic-wall-street-rally-gold-gains-slightly">markets soared</a>, prompting CNBC's Jim Cramer to share major lessons to be learned from the recent market chaos.
What Happened: Major indices like the Dow, S&amp;P 500, and Nasdaq <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44721874/trumps-tariff-pause-saves-market-from-edge-of-the-cliff-dan-ives-says-biggest-wild-card-still-remains">rebounded significantly</a> after the pause was announced. Cramer stressed that "Nobody ever made a dime panicking," urging investors to stay the course rather than make hurried, emotionally-charged decisions.
See Also: <a href="https://www.benzinga.com/markets/25/04/44727180/cramer-praises-trump-for-pushback-on-nippon-dumper-steel-calls-the-block-a-smart-move">Cramer Praises Trump For Pushback On Nippon &#8216;Dumper&#8217; Steel, Calls The Block A &#8216;Smart Move&#8217;</a>
Why It Matters: "Staying the course is how you make the biggest money," Cramer said, observing that stockholders typically make their annual gains on just a few crucial days.
He also drew attention to the unpredictability of the political climate, noting that "the president likes drama — you won't get certainty," reminding investors to expect policy shifts and stay away from knee-jerk reactions.
Despite market instability, Cramer's key message is clear: "Bulls make money, bears make money, pigs get slaughtered."
His advice is to bet on strong, proven companies, which he reiterated as shares of major <a href="https://www.benzinga.com/trading-ideas/movers/25/04/44724362/chip-stocks-surge-as-trump-pauses-tariffs-for-us-allies-targets-china-with-125-duties">tech firms</a> like Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) and Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) rebounded sharply on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44681272/jim-cramer-questions-market-strength-amid-chinas-retaliatory-tariffs-oversold-panic-or-a-big-trap">Jim Cramer Cautions Against Jumping In As Oversold Market Sparks Futures Rebound Without Clear Catalyst: &#8216;Is It All A Big Trap?&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

Opinion

AAPL

NVDA

Jim Cramer Reminds Investors 'Nobody Ever Made A Dime Panicking' After Market Rally Amid Tariff Pause

HC Wainwright &amp; Co. analyst Heiko Ihle reiterates Endeavour Silver (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXK#NYSE">EXK</a>) with a Buy and maintains $7.25 price target.

HC Wainwright & Co. Reiterates Buy on Endeavour Silver, Maintains $7.25 Price Target

Press Releases

MeiraGTx Announces Poster Presentation on a Potential Treatment for MC4R Genetic Deficiency at the 2024 Society for Neuroscience Conference

Health Care

MeiraGTx Announces Positive Data from Randomized, Sham-controlled Clinical Bridging Study of AAV-GAD for the Treatment of Parkinson's Disease

MeiraGTx Announces Five Posters at the European Society of Gene and Cell Therapy (ESGCT) 2024 Annual Congress

MeiraGTx Announces Third Quarter 2024 Financial and Operational Results and Recent Business Updates

Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors

MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

MeiraGTx Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaurosis due to GUCY2D Mutations

MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy

Contracts

MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson's Disease and Industrialize MeiraGTx's Proprietary Manufacturing Process

Comments

MeiraGTx Hldgs

Noticias

Últimas noticias sobre MeiraGTx Hldgs (NASDAQ:MGTX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL